HR 2372 Introduced Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
To amend the Federal Food, Drug, and Cosmetic Act to enhance medical device communications and ensure device cleanliness.
Summary
This bill requires medical device manufacturers to notify the FDA before making changes to device design or reprocessing instructions, and to report certain communications about design changes, reprocessing changes, or safety concerns that are sent to foreign health care providers within five days. The bill adds "rapid assessment tests" (tests used to verify that reusable medical devices have been properly cleaned and sterilized) to the FDA's definition of medical devices. The FDA must develop a list within one year identifying which rapid assessment tests require validated instructions for use and supporting validation data, and must periodically update this list. Manufacturers seeking FDA approval for rapid assessment tests on this list must provide the required instructions and data.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
- Rep. Lieu, Ted [D-CA-36] (D-CA)
2 cosponsors
Money behind the sponsor
Top reported contributors to Ted Lieu’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- NOT-EMPLOYED $255,097
- NULL $21,050
- COTCHETT, PITRE & MCCARTHY, LLP $13,200
- TRENDNET $13,200
- NETFLIX $13,200
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Ted Lieu → · Outside spending →
Actions (2)
- Mar 26, 2025 Referred to the House Committee on Energy and Commerce. · house
- Mar 26, 2025 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Text versions (1)
Bills are re-published as they move (Introduced → Reported → Engrossed → Enrolled …). Each stage below is a separate text; pick two to see what changed. Data from Congress.gov.
Full text
IN THE HOUSE OF REPRESENTATIVES
March 26, 2025
Mr. Lieu (for himself, Ms. Chu, and Ms. Norton) introduced the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To amend the Federal Food, Drug, and Cosmetic Act to enhance medical device communications and ensure device cleanliness.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Disclosure; and Encouragement of Verification, Innovation, Cleaning, and Efficiency Act of 2025” or the “DEVICE Act of 2025”.
SEC. 2. REPORTING REQUIREMENT FOR DESIGN AND REPROCESSING INSTRUCTION CHANGES.
(a) Adulteration.—Section 501 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351) is amended by inserting after paragraph
(j) the following:
“(k) If it is a device with respect to which the manufacturer is in violation of the reporting requirement under section 510(r) (relating to design and reprocessing changes).”.
(b) Requirement.—Section 510 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360) is amended by adding at the end the following:
“(r) Reporting Requirement for Device Design Changes.—Before making a change to the design of a device, or the reprocessing instructions of a device, that is marketed in interstate commerce, the manufacturer of the device shall give written notice of the change to the Secretary.”.
SEC. 3. REPORTING REQUIREMENT FOR CERTAIN COMMUNICATIONS TO FOREIGN HEALTH CARE PROVIDERS.
(a) Adulteration.—Section 501 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351), as amended by section 2 of this Act, is further amended by inserting after paragraph (k) the following:
“(l) If it is a device with respect to which the manufacturer is in violation of the reporting requirement under section 510(s) (relating to communications to foreign health care providers).”.
(b) Requirement.—Section 510 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360), as amended by section 2 of this Act, is further amended by adding at the end the following:
“(s) Reporting Requirement for Certain Communications to Foreign Health Care Providers.—
“(1) Requirement.—The manufacturer of a device that is marketed in interstate commerce shall give written notice to the Secretary of any communication described in paragraph (2) not more than 5 calendar days after making such communication.
“(2) Communication described.—A communication is described in this paragraph if the communication—
“(A) is made by the manufacturer of the device or an affiliate of the manufacturer;
“(B) relates to a change to the design of the device, a change to the recommended reprocessing protocols, if any, for the device, or a safety concern about the device; and
“(C) is widely disseminated (including on a voluntary basis) to health care providers in a foreign country.
“(3) Affiliate.—In this subsection, the term ‘affiliate’ means a business entity that has a relationship with a second business entity if, directly or indirectly—
“(A) one business entity controls, or has the power to control, the other business entity; or
“(B) a third party controls, or has the power to control, both of the business entities.”.
SEC. 4. RAPID ASSESSMENT TESTS INTENDED TO ENSURE PROPER REPROCESSING.
(a) Inclusion in Device Definition.—Section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321) is amended—
(1) in paragraph (h)(1)—
(A) in clause (B), by striking “or” at the end;
(B) in clause (C), by striking “and” at the end and inserting “or”; and
(C) by inserting after clause (C) the following:
“(D) a rapid assessment test intended to ensure the proper reprocessing of a reusable device (as defined in paragraph (tt)), and”; and
(2) by adding at the end the following: “(tt) The term ‘reusable device’ means a device that—
“(1) is intended to be used more than one time; and
“(2) must be sanitized (whether through cleaning, disinfection, or sterilization) to ensure that the device is safe and effective for such intended use.”.
(b) Instructions for Use and Validation Data.—Section 510 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360), as amended by sections 2 and 3 of this Act, is further amended by adding at the end the following:
“(t) Instructions for Use and Validation Data.—
“(1) Initial list.—Not later than 1 year after the date of enactment of this subsection, the Secretary shall by regulation develop and publish a list of types of rapid assessment tests described in section 201(h)(1)(D) for which reports under subsection (k) must include—
“(A) instructions for use that have been validated in a manner specified by the Secretary; and
“(B) validation data, of the types specified by the Secretary.
“(2) Updates.—The Secretary shall by regulation periodically update the list required by paragraph (1).
“(3) Enforcement.—Beginning on the date of publication of the initial list under paragraph (1), the Secretary shall not accept any notification under subsection (k) for clearance of a type of rapid assessment test that is included on such list unless such notification includes instructions for use and validation data in accordance with paragraph (1).”. <all>
Comments